Literature DB >> 9472725

Fractional removal rate of fat emulsion (K2) remains to be low in APOE3/3 phenotype subjects with serum triglyceride level above 180mg/dl.

R Ikeuchi1, N Sakuma, J Hayano, T Fujinami.   

Abstract

The relation between fractional catabolic rate (K2) of an intravenously injected fat emulsion, Intralipid, and the level of serum triglyceride (TG) was evaluated to cast light on TG-rich lipoprotein metabolism in 182 subjects who were homozygotes for the most common form of apoE3/3. Both normolipidemic individuals and primary hyperlipidemic patients were included. To assess the influence of variation in the apoE phenotype on fat emulsion metabolism, 25 subjects with the apoE 4/3 phenotype and 21 with apoE 3/2 phenotype were also evaluated. In the apoE 3/3 subjects, K2 decreased with increasing TG level up to 180mg/dl, but above 180mg/dl, K2 remained at a constant level. This TG value was therefore concluded to be a cut off beyond which the TG-dependent decrease in K2 disappeared. No apparent correlation between K2 and serum TG was observed in subjects with apoE 4/3 or 3/2 phenotypes. In subjects with TG above 180mg/dl, presumably both accelerated synthesis and limited removal are involved in the development of their hypertriglyceridemia. Since K2 demonstrated little change with increase of TG over 180mg/dl in apoE 3/3 subjects, we concluded that the capacity to catabolize fat emulsion reaches a kinetic saturation. The TG value of 180mg/dl may be a physiological significance. The relation between K2 and TG was specific in apoE 3/3, as it was not observed in subjects having apoE 4/3 or 3/2 phenotypes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472725     DOI: 10.1016/s0024-3205(97)01161-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  1 in total

1.  Increased serum triglyceride clearance and elevated high-density lipoprotein 2 and 3 cholesterol during treatment of primary hypertriglyceridemia with bezafibrate.

Authors:  Nagahiko Sakuma; Reiko Ikeuchi; Takeshi Hibino; Takayuki Yoshida; Seiji Mukai; Sachie Akita; Kazuhiro Yajima; Hiromichi Miyabe; Toshihiko Goto; Norio Takada; Nobuyuki Ohte; Mitoshi Kunimatu; Genjiro Kimura
Journal:  Curr Ther Res Clin Exp       Date:  2003-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.